I
Itziar de Aguirre
Researcher at Laboratory of Molecular Biology
Publications - 22
Citations - 5912
Itziar de Aguirre is an academic researcher from Laboratory of Molecular Biology. The author has contributed to research in topics: Lung cancer & non-small cell lung cancer (NSCLC). The author has an hindex of 11, co-authored 22 publications receiving 5293 citations. Previous affiliations of Itziar de Aguirre include Emory University.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations
Rafael Rosell,Miguel Angel Molina,Carlota Costa,Sara Simonetti,Anna Gimenez-Capitan,Jordi Bertran-Alamillo,Clara Mayo,Teresa Moran,Pedro Mendez,Felipe Cardenal,Dolores Isla,Mariano Provencio,Manuel Cobo,A. Insa,Rosario García-Campelo,Noemi Reguart,Margarita Majem,Santiago Viteri,Enric Carcereny,R. Porta,Bartomeu Massuti,Cristina Queralt,Itziar de Aguirre,Jose Miguel Sanchez,Maria Sanchez-Ronco,Jose Luis Mate,Aurelio Ariza,Susana Benlloch,Jose Javier Sanchez,Trever G. Bivona,Charles L. Sawyers,Miquel Taron +31 more
TL;DR: Low BRCA1 levels neutralized the negative effect of the T790M mutation and were associated with longer progression-free survival to erlotinib.
Journal ArticleDOI
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
Niki Karachaliou,Clara Mayo de las Casas,Cristina Queralt,Itziar de Aguirre,Boris Melloni,Felipe Cardenal,Ramon Garcia-Gomez,Bartomeu Massuti,Jose Miguel Sanchez,R. Porta,Santiago Ponce-Aix,Teresa Moran,Enric Carcereny,Enriqueta Felip,Isabel Bover,A. Insa,Noemi Reguart,Dolores Isla,Alain Vergnenegre,Filippo de Marinis,Radj Gervais,Romain Corre,Luis Paz-Ares,Daniela Morales-Espinosa,Santiago Viteri,Ana Drozdowskyj,Núria Jordana-Ariza,Jose L uis Ramirez-Serrano,Miguel Angel Molina-Vila,Rafael Rosell +29 more
TL;DR: The peptide nucleic acid-mediated 5´ nuclease real-time polymerase chain reaction (TaqMan) assay used in this study can be used to efficiently assess EGFR mutations in cfDNA and may be a novel surrogate prognostic marker.
Journal ArticleDOI
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
Imane Chaib,Niki Karachaliou,Sara Pilotto,Jordi Codony Servat,Xueting Cai,Xueting Cai,X. Li,Ana Drozdowskyj,Carles Codony Servat,Jie Yang,Jie Yang,Chunping Hu,Chunping Hu,Andrés F. Cardona,Guillermo López Vivanco,Alain Vergnenegre,Jose Miguel Sanchez,Mariano Provencio,Filipo de Marinis,Antonio Passaro,Enric Carcereny,Noemi Reguart,Charo Garcia Campelo,Christina Teixido,Isabella Sperduti,Sonia Rodríguez,Chiara Lazzari,Alberto Verlicchi,Itziar de Aguirre,Cristina Queralt,Jia Wei,Roger Estrada,Raimon Puig de la Bellacasa,Jose Luis Ramirez,Kirstine Jacobson,Henrik J. Ditzel,Mariacarmela Santarpia,Mariacarmela Santarpia,Santiago Viteri,Migual Angel Molina,Caicun Zhou,Peng Cao,Peng Cao,Patrick C. Ma,Trever G. Bivona,Rafael Rosell +45 more
TL;DR: This study uncovers a coordinated signaling network centered on both STAT3 and Src-YAP signaling that limits targeted therapy response in lung cancer and identifies an unforeseen rational upfront polytherapy strategy to minimize residual disease and enhance clinical outcomes.
Journal ArticleDOI
Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients.
Jose Luis Ramirez,Carme Sarries,Pedro López de Castro,Barbara Roig,Cristina Queralt,Daniel Escuin,Itziar de Aguirre,Jose Miguel Sanchez,Jose Luis Manzano,Mireia Margeli,Jose Javier Sanchez,Julio Astudillo,Miquel Taron,Rafael Rosell +13 more
TL;DR: Gene methylation and K-ras mutations were examined in tumor and paired serum DNA of 50 resected non-small-cell lung cancer patients and correlated significantly with survival, but no correlation was found with survival.